Virax Biolabs GroupVRAX
13F holders, Q1 2026 (March 31)3holders −2
2new positions
4sold out
$0.22avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings, down 2 from Q4 2025. 2 opened new positions and 4 sold out. The largest holders were Armistice Capital, LLC ($193K), Jump Financial, LLC ($9K) and Osaic Holdings, Inc. ($4).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $202K |
| Exits | 4 | $12K |
All 13F filers, Q4 2025 → Q1 2026: 919,527 shares bought and 34,939 shares sold, net +884,588 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Armistice Capital, LLC | 0.01% | New | 878,803 | $193K |
| Jump Financial, LLC | 0.00% | New | 40,724 | $9K |
| Osaic Holdings, Inc. | 0.00% | No change | 20 | $4 |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.